Switch theme
Sign up to access all valuation multiples
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company’s in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
2018
60
Last FY Revenue n/a
LTM EBITDA -$115M
$171M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Tyra Biosciences has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$115M.
In the most recent fiscal year, Tyra Biosciences achieved revenue of n/a and an EBITDA of -$104M.
Tyra Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Tyra Biosciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$115M | XXX | -$104M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$118M | XXX | -$104M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$103M | XXX | -$86.5M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Tyra Biosciences's stock price is $9.
Tyra Biosciences has current market cap of $484M, and EV of $171M.
See Tyra Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $171M | $484M | XXX | XXX | XXX | XXX | $-1.76 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Tyra Biosciences has market cap of $484M and EV of $171M.
Tyra Biosciences's trades at n/a EV/Revenue multiple, and -1.7x EV/EBITDA.
Equity research analysts estimate Tyra Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tyra Biosciences has a P/E ratio of -4.7x.
See valuation multiples for Tyra Biosciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $484M | XXX | $484M | XXX | XXX | XXX |
| EV (current) | $171M | XXX | $171M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -1.5x | XXX | -1.7x | XXX | XXX | XXX |
| EV/EBIT | -1.4x | XXX | -1.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.7x | XXX | -5.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTyra Biosciences's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.7M for the same period.
Tyra Biosciences's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Tyra Biosciences's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Tyra Biosciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tyra Biosciences acquired XXX companies to date.
Last acquisition by Tyra Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Tyra Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Tyra Biosciences founded? | Tyra Biosciences was founded in 2018. |
| Where is Tyra Biosciences headquartered? | Tyra Biosciences is headquartered in United States of America. |
| How many employees does Tyra Biosciences have? | As of today, Tyra Biosciences has 60 employees. |
| Who is the CEO of Tyra Biosciences? | Tyra Biosciences's CEO is Dr. Todd Harris, PhD. |
| Is Tyra Biosciences publicy listed? | Yes, Tyra Biosciences is a public company listed on NAS. |
| What is the stock symbol of Tyra Biosciences? | Tyra Biosciences trades under TYRA ticker. |
| When did Tyra Biosciences go public? | Tyra Biosciences went public in 2021. |
| Who are competitors of Tyra Biosciences? | Similar companies to Tyra Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Tyra Biosciences? | Tyra Biosciences's current market cap is $484M |
| Is Tyra Biosciences profitable? | Yes, Tyra Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Tyra Biosciences? | Tyra Biosciences's last 12 months EBITDA is -$115M. |
| What is the current EV/EBITDA multiple of Tyra Biosciences? | Current EBITDA multiple of Tyra Biosciences is -1.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
